Nexien Biopharma Corp is a clinical-stage biotechnology company focused on the development of novel therapies for oncology and central nervous system disorders. Leveraging a proprietary peptide-based delivery platform, Nexien aims to improve the targeting and efficacy of therapeutic molecules by facilitating their transport across biological barriers such as the blood-brain barrier. The company’s research pipeline includes targeted immuno-oncology candidates designed to harness and enhance the body’s natural immune response against solid tumors, as well as peptide constructs intended to address neurological conditions.
The company’s lead oncology programs are in preclinical or early clinical development and are designed to tackle hard-to-treat cancers, including glioblastoma, triple-negative breast cancer and metastatic melanoma. Using its modular delivery system, Nexien is developing peptide-drug conjugates and checkpoint-modulating agents that aim to maximize tumor cell kill while minimizing off-target effects. In parallel, Nexien is advancing a peptide-based platform for central nervous system disorders, with an initial focus on neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Nexien Biopharma conducts its research and early development activities primarily in the United States, with laboratory facilities located in San Diego, California. The company has established preclinical testing collaborations with academic institutions in Europe and North America and is in discussions with potential strategic partners to support later-stage clinical development and global commercialization. Through these collaborations, Nexien seeks to leverage external expertise and accelerate the translation of its peptide therapeutics from the laboratory to the clinic.
Founded in 2018 as a spin-out from university research, Nexien Biopharma is led by an experienced management team with deep expertise in drug development, peptide chemistry and pharmaceutical operations. Chief Executive Officer Jennifer Hsu, Ph.D., brings more than 20 years of biopharma leadership, while Chief Scientific Officer Michael Adler, Ph.D., is a recognized authority on peptide delivery technologies. The board and scientific advisory committee feature seasoned professionals in oncology, neurology and immunology, underscoring the company’s commitment to advancing innovative treatments for patients with unmet medical needs.
AI Generated. May Contain Errors.
